Clinical Trial Update: To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden [Phase 2]

View source ↗

Summary

Phase 2 study sponsored by AstraZeneca compares PET measurements of fibrillar amyloid burden in Alzheimer's disease. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: AstraZeneca | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED